InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,995.54
(
0.38%
)
US TECH 100
20,656.40
(
0.44%
)
Dow Jones
43,988.99
(
0.00%
)
Brent Oil
72.27
(
-1.95%
)
Bitcoin
81,869.65
(
1.72%
)
Post# of 253567
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120700
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 240599

Tuesday, 12/14/2021 7:12:56 PM

Tuesday, December 14, 2021 7:12:56 PM

Post# of 253567
FDA approves Xeljanz for second-line ankylosing spondylitis:

https://finance.yahoo.com/news/u-fda-approves-pfizer-xeljanz-210800921.html

The second-line restriction (following TNF-a treatment in the first line) is a consequence of the label changes for JAK inhibitors generally in inflammatory diseases (#msg-167001417).

Xeljanz now has FDA approved indications in second-line: RA; PsA; AS (above); and UC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up